ARCHIVES

ODAC Recommends Approval of Evista for Breast Cancer Risk Reduction.

This article is from The Cancer Letter archive.

Vol. 33 No. 29 | July 27, 2007

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI To Push “Cancer Prevention Awareness” This Month; Three RFPs Delayed For Changes

February 17, 1984

Upton Struggling To wrap Up Reorganization Of DCCR Before Next Week’s Meeting Of NCAB

September 28, 1979

Opioid Pain Reliever Approved With Risk Reduction Plan

July 31, 2009

FDA, Genentech Agree On Framework for Avastin Hearing June 28-29

April 8, 2011

In Brief: Bioassay Prime Contract Renewed For Four Years, $34.2 Million; Canellos Quits As Clinical Director

June 20, 1975

NIAID Advisors Ok Recompetition of Pediatric ACTGs

February 14, 1992